RxDoctor Payments DataLook up a doctor →

Robert Rifkin, MD

Psychiatry · Saint Louis, MONPI 1639289051

Payments from drug & device makers

$14,818in general payments, 2019–2025

Across 848 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • Axsome Therapeutics, Inc.$925
  • Alkermes, Inc.$752
  • plus $7K from 32 others

What the payments were for

  • Food & beverage$14,745100%
  • Education$720%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,818 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$91,217
Medicare patients
234
Services billed
888

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl43$50,358
Abilify MaintenaAripiprazole12$33,293
TrintellixVortioxetine Hydrobromide19$23,812
VraylarCariprazine Hcl16$22,447
CaplytaLumateperone Tosylate12$19,618
BelsomraSuvorexant25$14,168
PristiqDesvenlafaxine Succinate15$12,578
VyvanseLisdexamfetamine Dimesylate23$10,606
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine143$8,485
Bupropion XlBupropion Hcl216$7,263
Aripiprazole158$6,564
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine209$6,123
Olanzapine138$5,492
Duloxetine Hcl250$5,234
Lisdexamfetamine Dimesylate22$5,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$464$50,35843 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$651$34,41842 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$1,793$33,29312 claims
AbbVieVraylar$1,391$22,44716 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$2,218$19,61812 claims
MerckBelsomra$151$14,16825 claims
Almatica Pharma LLCSertraline Hcl$58$1,289160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →